Armata Pharmaceuticals, Inc. (ARMP) stock
Close on Nov 11, 2026Market cap $144.64MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2026
Valuation
- Market cap
- $144.64M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- -18.57%
Fundamentals
- Net income
- -$110.65M
- EPS, diluted
- -$7.09
- Free cash flow
- -$26.86M
- Book value per share
- -$2.78
- Diluted shares
- 63M
Trading
- Next earnings
- Nov 11, 2026 (estimated, during market hours)
- Previous close
- $3.75
- Open
- $3.73
- Day's range
- $3.57 – $3.89
- Volume
- 50,549
- Average volume (20 days)
- 83,400
- Index membership
- Russell 2000 (since Jun 2026)
- Beta (5 years)
- 0.86
- 52-week range
- $2.75 – $14.98
- RSI (14 days)
- 57.2
- Volatility (1 year)
- 112.8%
- Relative volume
- 0.28×
- WACC
- 9.2%
Index membership is inferred from the holdings of funds that track each index (IWM), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2014, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ARMP | S&P 500 | Difference | ARMP per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +7.2% | -2.4% | +9.6 pts | ||
| 3 months | -8.5% | -1.2% | −7.3 pts | ||
| Year to date | -38.1% | +12.3% | −50.3 pts | ||
| 1 year | -42.4% | +12.4% | −54.8 pts | ||
| 3 years | +50.8% | +78.8% | −28.0 pts | +14.7% | +21.4% |
| 5 years | +14.7% | +75.2% | −60.4 pts | +2.8% | +11.9% |
| 10 years | -97.2% | +311.1% | −408.3 pts | -30.0% | +15.2% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Armata Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- News
- Update
- Results
- Update
- Update
- News
About Armata Pharmaceuticals
Biological Products, (No Diagnostic Substances)
Armata is a late clinical-stage biotechnology company that develops pathogen-specific bacteriophage therapeutics to treat antibiotic-resistant and difficult-to-treat bacterial infections. Using proprietary host-engineered manufacturing techniques, the company produces bacteriophages designed to eliminate targeted pathogens while preserving the normal human microbiome. Its pipeline includes AP-PA02, an inhaled candidate evaluated for chronic pulmonary Pseudomonas aeruginosa infections in patients with cystic fibrosis and non-cystic fibrosis bronchiectasis, and AP-SA02, an intravenous candidate evaluated for complicated Staphylococcus aureus bacteremia. It also evaluates AP-PA03 for acute ventilator-associated pneumonia. Its therapies serve patients suffering from severe bacterial infections.
Company profile, executives and historyArmata Pharmaceuticals stock: common questions
What is Armata Pharmaceuticals's stock price?
ARMP closed at $3.89 on Nov 11, 2026, up 3.73% on the day. Over the past 52 weeks it traded between $2.75 and $14.98.
What is Armata Pharmaceuticals's market cap?
Armata Pharmaceuticals was worth $144.64M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ARMP's P/E ratio?
Armata Pharmaceuticals lost money over the twelve months to Sep 30, 2026 (diluted EPS -$7.09), so it has no meaningful P/E ratio.
Does Armata Pharmaceuticals pay a dividend?
No. Armata Pharmaceuticals has not paid a cash dividend over the last twelve months.
When does Armata Pharmaceuticals report earnings next?
Armata Pharmaceuticals is expected to report Q3 FY2026 results on Nov 11, 2026, during market hours. The date is estimated from its past reporting pattern until the company confirms it.
How has ARMP stock performed over the past year?
Including dividends, ARMP returned -42.4% over the past year, against +12.4% for the S&P 500.
Who are Armata Pharmaceuticals's competitors?
Companies most similar to Armata Pharmaceuticals by business, industry and size include PCVX, VIR, ZURA, DTIL, ELOX.
See a number that looks wrong?